Redefining Reliever Therapy: Budesonide-Formoterol Outperforms SABA in Controlling Airway Inflammation Among Patients on Maintenance Corticosteroids
Posted inAllergy & Immunology news Respiratory

Redefining Reliever Therapy: Budesonide-Formoterol Outperforms SABA in Controlling Airway Inflammation Among Patients on Maintenance Corticosteroids

The INFORM ASTHMA trial demonstrates that budesonide-formoterol as a reliever significantly reduces Type 2 airway inflammation (FeNO) compared to terbutaline in adults already using maintenance inhaled corticosteroids, establishing a new evidence base for anti-inflammatory reliever strategies in moderate asthma.